Updates are available Correction dated 2023-02-15
Click to view Correction: https://doi.org/10.1038/s41584-023-00929-1
-
Authors
McMahan, Zsuzsanna H. http://orcid.org/0000-0003-1412-4453
Kulkarni, Subhash
Chen, Joan http://orcid.org/0000-0001-9425-3209
Chen, Jiande Z.
Xavier, Ramnik J. http://orcid.org/0000-0002-5630-5167
Pasricha, P. Jay
Khanna, Dinesh
- License Information
-
More Information
Article History
Accepted: 20 December 2022
First Online: 6 February 2023
Change Date: 15 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41584-023-00929-1
Competing interests
: J.C. declares that she is a consultant for Phathom Pharmaceuticals. R.J.X. declares that he is co-founder of Jnana Therapeutics and Celsius Therapeutics, a board member for Moonlake Immunotherapeutics and on the Scientific Advisory Board for Nestle. P.J.P. declares that he is co-founder of, holds equity in and is a consultant for Neurogastrx. D.K. declares that he has received consulting fees from Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech/Roche, Horizon, Paracrine Cell Therapy, Mitsubishi Tanabe Pharma, Prometheus and Theraly. Z.H.M., S.K. and J.Z.C. declare no competing interests.
